Recent news on Abciximab

Bivalirudin as Effective as Heparin in Acute Coronary Syndromes ...  -  May 14, 2007
DG NewsBivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the

Medicure's Aggrastatr Highlighted in Expert Opinion Journal  -  Apr 20, 2007
PharmaLive.com (press release),..."The available data suggests that high-dose bolus tirofiban may be as effective and safe as abciximab in patients undergoing PCI.

Study Identifies Steps To Improve Safety Of Renal Artery Stenting  -  Apr 3, 2007
Science Daily (press release)Abciximab reduced the occurrence of platelet-rich emboli (particles or debris) in the EPD from 42 to seven percent. This difference was highly significant

The Moose in the Room  -  Apr 16, 2007
Scientist,A significant part of this job was maintaining a strategic alliance with the then-independent Centocor to market the antithrombotic drug, ReoPro (abciximab)

Kidney stent helps lower blood pressure  -  Mar 31, 2007
Toledo Blade,And a quarter received the stent, the filter, and the platelet drug, Abciximab. The research found that patients given both the drug and the filter with

Trial Looks at Timing of Anti-Clotting Drugs for Heart Attack Patients  -  Feb 13, 2007
Atlanta Journal Constitution (subscription),But glycoprotein IIb/IIIa inhibitors, which include abciximab or eptifibatide, can also help cut clotting risks. "All of the guidelines do recommend the use

Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation ...  -  Jan 17, 2007
HeartZine,Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex.

Medicure Completes US$25.9 Million Private Placement  -  Dec 28, 2006
Genetic Engineering News (press release),The meta-analysis suggests that Single High-Dose Bolus tirofiban may be as effective as abciximab in patients undergoing PCI with a comparable safety

Medicure Announces Second Quarter Fiscal 2007 Financial Results  -  Jan 12, 2007
PharmaLive.com (press release),The Company announced that new data comparing Single High-Dose Bolus AGGRASTATR (tirofiban) versus ReoProR (abciximab) in patients undergoing percutaneous

Primary PCI for Myocardial Infarction with ST-Segment Elevation  -  Jan 3, 2007
New England Journal of Medicine (subscription),Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117.

Abciximab Helpful in Thrombosis During Intracranial Aneurysm ...  -  Dec 4, 2006
DG NewsIn what is believed to be the largest case series evaluation of the use of abciximab in this setting, researchers found that use of the drug was associated

Abciximab reduces risk of adverse events for patients with acute ...  Oct 11, 2006
...a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug Abciximab ( ReoPro ). ... -Xagena.it, Medicure Announces New Aggrastat'R' Data to be Presented at 2006 ...  Nov 6, 2006
...that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTAT ® (tirofiban) and ReoPro ® (abciximab) in patients ... -CCNMatthews (press release), Medicure Announces New Aggrastat Data to Be Presented at 2006 ...  Nov 6, 2006
...that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTATR (tirofiban) and ReoProR (abciximab) in patients ... -PharmaLive.com (press release), GP IIb/IIIa inhibition: Time to drop the infusion?  Oct 11, 2006
...whereas in the GP IIb/IIIa arm, they gave the FDA-approved dose: they ran [abciximab or eptifibatide] for 12 to 24 hours, because that's what's in the package ... -TheHeart.Org, HAAMU-STENT: Less late loss in STEMI patients treated with drug ...  Oct 27, 2006
2006 meeting. Patients were part of the larger HAAMU trial that compared abciximab-facilitated PCI with thrombolysis. "It seems ... -TheHeart.Org, TCT: One-Year Data Confirm Benefit of Stem Cell Therapy After MI  Oct 26, 2006
REPAIR-AMI was supported by a grant from Guidant, which also provided the balloon catheters. Eli Lilly supplied ReoPro (abciximab). ... -MedPage Today, Fondaparinux in Patients With ST-Segment Elevation Myocardial ...  Oct 31, 2006
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial ... -Journal of American Medical Association (subscription), Roadmap To Integrin Activation Created By UCSD Researchers  Sep 21, 2006
Direct inhibitors of GPIIb-IIIa binding include antithrombotics such as eptifibatide (Integrelin), abciximab (Reopro), and tirofiban (Aggrestat), drugs that ... -Medical News Today

Benefit Seen for Bone Marrow Treatment Following Heart Attack  Sep 20, 2006
REPAIR-AMI was supported by a grant from Guidant, which also provided the balloon catheters. Eli Lilly supplied ReoPro (abciximab). ... -MedPage Today

VIAMI: Post-thrombolytic PCI guided by viability testing cuts ...  Sep 5, 2006
...recurrent ischemia. Percutaneous intervention consisted of coronary stenting accompanied by the antiplatelet agent abciximab. The ... -TheHeart.Org

Abciximab Helpful in Thrombosis During Intracranial Aneurysm ...  -  Dec 11, 2006
DG NewsIn what is believed to be the largest case series evaluation of the use of abciximab in this setting, researchers found that use of the drug was associated

Medicure Announces New Aggrastatr Data at 2006 Scientific Sessions ...  -  Nov 14, 2006
PharmaLive.com (press release),The study results demonstrated an event rate for the 30-day composite of 6.1% with tirofiban and 7.3% with abciximab (p=0.46). There were no significant

Endovascular Mechanical Clot Retrieval in a Broad Ischemic Stroke ...  -  Nov 16, 2006
AJNR (subscription),Three patients unresponsive to device therapy received rescue intra-arterial tPA/abciximab; recanalization was achieved in 2/3.

New Trials of Antithrombotic Therapy for ACS -- ACC 2006  Jul 21, 2006
The patients were then randomized to receive abciximab at the standard dosing vs placebo, and the primary endpoint looked at death, MI, or urgent ... -Medscape (subscription)



Similar Early Outcomes With Eptifibatide and Abciximab Before ...  16 May 2006
CHICAGO, IL -- May 15, 2006 -- The glycoprotein IIb/IIIa inhibitors abciximab and eptifibatide appear to be equally effective in improving in-hospital outcomes ... - DG News

Mechanisms Behind Rare Clotting Disorder Exposed  Apr 21, 2006
In addition, this receptor is also the target for several anti-platelet agents, such as ReoPro (abciximab), a monoclonal antibody that inhibits platelet ... - MedPage Today





Abciximab Improves PCI Outcome in Acute Coronary Syndrome  Apr 5, 2006
PCI) after pretreatment with clopidogrel, additional treatment with the platelet glycoprotein IIb/IIIa inhibitor abciximab prevents postprocedural ischemic ... - Medscape (subscription)

Abciximab in Patients With Acute Coronary Syndromes Undergoing ...  Apr 4, 2006
Context No specifically designed studies have addressed the role of the glycoprotein IIb/IIIa inhibitor abciximab in patients with non–ST-segment elevation ... - Journal of American Medical Association (subscription)

Adding abciximab to the antithrombotic regimen significantly ...  Mar 18, 2006
Previous research has shown that adding the antithrombotic drug abciximab, (a glycoprotein IIb/IIIa receptor inhibitor) to therapy with ticlopidine plus ... - RxPG NEWS

Clopidogrel Treatment Prior to Percutaneous Coronary Intervention  Apr 4, 2006
Abciximab, eptifibatide, and tirofiban were studied in several placebo-controlled trials involving nearly 17 000 patients undergoing nonemergent PCI. ... - Journal of American Medical Association (subscription)

This Week in JAMA  Apr 4, 2006
...elevation acute coronary syndromes having percutaneous coronary intervention after pretreatment with 600 mg of clopidogrel received abciximab or placebo to ... - Journal of American Medical Association (subscription)

Clopidogrel reduces risk of adverse events for patients with acute ...  Mar 14, 2006
...a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug abciximab, according to ... - News-Medical.net

Blood Thinner Protects Heart Patients  Mar 14, 2006
TUESDAY, March 14 (HealthDay News) -- The anti-clotting drug abciximab reduced the risk of heart attack and other adverse events in heart patients receiving ... - Forbes

Post-stent questions raised  Mar 16, 2006
Previous research has shown that adding the anti-thrombotic drug abciximab to therapy with ticlopidine plus aspirin significantly reduces post-stent ... - myDNA.com

Recommendations for Anticoagulated Patients Undergoing Image ...  Mar 21, 2006
This class of antiplatelet drugs includes abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat). Normal platelet ... - Am J Neuroradiology (subscription)

3 UK Cardiologists Offer Insight in Latest Issues of JAMA  Mar 13, 2006
In addition to the anti-clotting drug clopidogrel, patients received a second “blood thinner,� abciximab. While the study found ... - UK News

Panel of Industry Experts Discuss Challenges of Finding Cures for ...  Mar 30, 2006
His research accomplishments include the development of a monoclonal antibody to platelets that was developed into the drug ReoPro(R) (abciximab), which is ... - PR Newswire

Blood Transfusions Appear to Harm Patients in Heart Procedures ...  Mar 16, 2006
Cardiology, Columbia University Medical Center, New York, New York, United States, scrutinized records of patients in the Controlled Abciximab and Device ... - DG News

ACC: ReoPro Lowers Risk of Adverse Events in Acute Coronary ...  Mar 13, 2006
...intervention after pre-treatment with Plavix (clopidogrel) have fewer adverse coronary events if they also get ReoPro (abciximab), investigators reported here ... - MedPage Today

Drug-eluting and absorbable stents push interventional frontiers  Mar 13, 2006
9,200 patients to receive either upfront GPI (eptifibatide or tirofiban) in the emergency room, or delayed, selective GPI (eptifibatide or abciximab) in the ... - EurekAlert

The Medicines Company: hoping for a coronary coup  Mar 7, 2006
MI) associated with ACS have recently been noted with the early addition of GPIIb/IIIa inhibitors such as Eli Lilly’s ReoPro (abciximab) and GlaxoSmithKline ... - Pharmaceutical Business Review

Renewal of Mural Thrombus Releases Plasma Markers and Is Involved ...  Feb 28, 2006
...induce aneurysms. Fifteen rats received abciximab treatment and fifteen received irrelevant immunoglobulins. Procoagulant activity ... - Am J Pathology (subscription)

Chairman of Cleveland Clinic Department of Cardiovascular Medicine ...  Feb 9, 2006
He was the first physician to administer recombinant t-PA, 2 different platelet glycoprotein IIb/IIIa inhibitors (abciximab and eptifibatide), and a new ... - International News Service,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional